CN115337276A - 一种新型的枸橼酸西地那非口腔崩解组合物 - Google Patents
一种新型的枸橼酸西地那非口腔崩解组合物 Download PDFInfo
- Publication number
- CN115337276A CN115337276A CN202110525787.3A CN202110525787A CN115337276A CN 115337276 A CN115337276 A CN 115337276A CN 202110525787 A CN202110525787 A CN 202110525787A CN 115337276 A CN115337276 A CN 115337276A
- Authority
- CN
- China
- Prior art keywords
- sildenafil citrate
- orally disintegrating
- disintegrating composition
- sildenafil
- spray
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960002639 sildenafil citrate Drugs 0.000 title claims abstract description 63
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 title claims abstract description 63
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims abstract description 24
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 20
- 239000008101 lactose Substances 0.000 claims abstract description 20
- 239000002245 particle Substances 0.000 claims abstract description 16
- 229960003310 sildenafil Drugs 0.000 claims abstract description 12
- 239000000463 material Substances 0.000 claims abstract description 9
- 239000011812 mixed powder Substances 0.000 claims abstract description 8
- OFPOBWHATCWYLY-RJMJUYIDSA-N OC(=O)CC(O)(C(O)=O)CC(O)=O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](O)C(O)O[C@@H]1CO Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](O)C(O)O[C@@H]1CO OFPOBWHATCWYLY-RJMJUYIDSA-N 0.000 claims abstract description 5
- 238000002156 mixing Methods 0.000 claims description 20
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 14
- 239000006191 orally-disintegrating tablet Substances 0.000 claims description 11
- 239000000314 lubricant Substances 0.000 claims description 7
- 235000019359 magnesium stearate Nutrition 0.000 claims description 7
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 6
- 238000010298 pulverizing process Methods 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
- 239000000796 flavoring agent Substances 0.000 claims description 5
- 235000013355 food flavoring agent Nutrition 0.000 claims description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 5
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 4
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 4
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 4
- 238000009826 distribution Methods 0.000 claims description 4
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 3
- 244000246386 Mentha pulegium Species 0.000 claims description 3
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 3
- 239000004376 Sucralose Substances 0.000 claims description 3
- 229960000913 crospovidone Drugs 0.000 claims description 3
- 239000007884 disintegrant Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 235000001050 hortel pimenta Nutrition 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 235000019408 sucralose Nutrition 0.000 claims description 3
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 3
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 229960005168 croscarmellose Drugs 0.000 claims description 2
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229940085605 saccharin sodium Drugs 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 20
- 238000004090 dissolution Methods 0.000 abstract description 10
- 238000000034 method Methods 0.000 abstract description 8
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 16
- 239000003826 tablet Substances 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 229910001220 stainless steel Inorganic materials 0.000 description 9
- 239000010935 stainless steel Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000013558 reference substance Substances 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 208000010228 Erectile Dysfunction Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 201000001881 impotence Diseases 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 2
- 239000013074 reference sample Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- -1 4-methylpiperazine-1-sulfonyl Chemical group 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- UNXNGGMLCSMSLH-UHFFFAOYSA-N dihydrogen phosphate;triethylazanium Chemical compound OP(O)(O)=O.CCN(CC)CC UNXNGGMLCSMSLH-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- NWJXSVNLQJZDLV-UHFFFAOYSA-N formic acid;hydrogen peroxide Chemical compound OO.OC=O NWJXSVNLQJZDLV-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000003245 working effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明属于药物制剂领域,具体涉及了一种含有枸橼酸西地那非和喷雾干燥乳糖的口腔崩解组合物及其制备方法。该药用组合物是由微粉化的枸橼酸西地那非‑喷雾干燥乳糖混粉与其他药学上可接受的辅料制备而成,组合物中枸橼酸西地那非粒度(D90)为15μm或更小。采用本发明提供的制备方法及药用组合所制得的西地那非口腔崩解片具有释放迅速、溶出完全、质量稳定、无需复杂制剂设备工艺、制备方法简单以及易于商业化生产的优点。
Description
技术领域
本发明属于药物制剂技术领域,具体而言,涉及一种含有口服枸橼酸西地那非的口腔崩解组合物及其制备方法。
背景技术
枸橼酸西地那非,化学名为1-甲基-3-正丙基-5-[2-乙氧基-5-(4-甲基哌嗪-1-磺酰基)苯基]-1,6-二氢-7H-吡唑并[4,2-d]嘧啶-7-酮枸橼酸盐,结构式如下所示:
枸橼酸西地那非是治疗阴茎勃起功能障碍(ED)的口服药。通过抑制磷酸二酯酶的水解活性来提高环磷酸鸟苷水平,而不影响环磷酸腺苷,从而增加性刺激引起的一氧化氮合成酶/环磷酸鸟苷瀑布作用,使海绵体平滑肌松弛,达到治疗勃起功能障碍的目的。近年来,多个研究表明,枸橼酸西地那非亦可用于肺动脉高压的治疗。
枸橼酸西地那非原料药具有较强的吸湿性,常态下易吸湿导致变质,现有技术中通过薄膜包衣材料将活性成分与空气隔绝或者添加生物制品来增加制剂的稳定性,存在制备工艺复杂、辅料安全性未知以及抑制片剂释放的缺点。
专利CN201510134423.7公开了一种枸橼酸西地那非片剂及其制备方法,通过将枸橼酸西地那非溶解在水中,再加入水溶性高的薄膜材料甲基纤维素,搅拌溶解后缓慢干燥,使甲基纤维素包覆在枸橼酸西地那非表面形成隔离膜,该法制作工艺较为复杂,且通过薄膜材料将西地那非与空气隔绝一定程度上降低了制剂的溶出性能。
与普通片剂相比,口腔崩解片能在不用水或少量水服用时在口腔内迅速崩解。口腔粘膜血管丰富,药物被吸收后通过颈内静脉到达心脏随血液循环向全身分布,可避免胃肠道的降解作用和肝脏首过作用,显效迅速,故可提高某些药物的生物利用度。
发明内容
为了克服现有技术不足,本发明的目的在于提供一种质量稳定、易于服用且制备工艺简单的枸橼酸西地那非口腔崩解组合物,该组合物中含有枸橼酸西地那非和喷雾干燥乳糖混粉。
本发明的另一目的在于提供上述枸橼酸西地那非组合物的制备方法。
为了实现上述目的,本发明所采用的技术方案是:
本发明一方面提供了一种枸橼酸西地那非口崩片,该口崩片含有喷雾干燥乳糖和微粉后的枸橼酸西地那非。喷雾干燥乳糖具有崩解性能良好、味道和口感良好以及流动性良好等优点,且其表面为多孔结构,能很好的吸附活性物质。将微粉后的枸橼酸西地那非和喷雾干燥乳糖放入混合机充分混合,使活性物质吸附在喷雾干燥乳糖表面的疏松多孔结构中,然后加入疏水性的润滑剂及药学上可接受的其他辅料制备,使活性物质与空气中的水分良好地隔绝,从而使口崩片拥有优良的稳定性;且喷雾干燥乳糖良好的崩解性能使患者在服用药物后迅速崩解,释放活性物质,使人体快速吸收。
本发明实施例还公开了枸橼酸西地那非药物组合物中活性成分对应于90%分布的颗粒直径(D90)的限定范围。经研究发现,药物组合物中活性成分枸橼酸西地那非经过微粉化并控制粒度D90≤15μm后,活性成分具有更大的比表面、空隙率和表面能,能更好地被吸附在喷雾干燥乳糖中,可显著提升药物的稳定性、溶解度以及吸收效果,并能控制药物的溶出速率。因此,本发明提供了一种含有枸橼酸西地那非和喷雾干燥乳糖的药用组合物,其活性成分枸橼酸西地那非的粒度(D90)为15μm 或更小。根据本发明的一些实施方式,本发明所公开的枸橼酸西地那非药物组合物中,活性成分枸橼酸西地那非的重量百分比为10%~20%(按西地那非计)。
另外,本发明所提供的药物组合物除包含微粉化枸橼酸西地那非-喷雾干燥乳糖混粉外,还包含崩解剂、填充剂、矫味剂和润滑剂。
本发明所述药用组合物中,其处方中选用的填充剂为甘露醇、三氯蔗糖、微晶纤维素中的一种或几种。根据本发明的一些实施方式,在单位剂型中含填充剂的重量百分比为10%~30%,优选5%~20%。
本发明所述药用组合物中,其处方中选用的崩解剂为交联羧甲基纤维素钠、交联聚维酮、交联羧甲基纤维素钙、羧甲基淀粉钠中的一种或几种。根据本发明的一些实施方式,在单位剂型中含崩解剂的重量百分比为2%~15%,优选4%~12%。
本发明所述药用组合物中,其处方中选用的矫味剂为甜菊素、薄荷香精、糖精钠中的一种或几种。根据本发明的一些实施方式,在单位剂型中含矫味剂的重量百分比为2%~10%,优选4%~8%。
本发明所述药用组合物中,其处方中选用的润滑剂为硬脂酸镁、胶态二氧化硅和滑石粉中的一种或几种。根据本发明的一些实施方式,在单位剂型中含润滑剂的重量百分比为1%~8%,优选3%~6%。
另一方面,本发明还提供了上述枸橼酸西地那非崩解片的制备方法,该方法包括如下步骤:
a)将枸橼酸西地那非粉碎至粒度 (D90) 为15μm 或更小;
b)将已处理的枸橼酸西地那非微粉、喷雾干燥乳糖加入三维混合机中,使其充分混合;
c)在所得枸橼酸西地那非-喷雾干燥乳糖混粉中加入其他辅料混合均匀,得到中间体颗粒,压片即得枸橼酸西地那非口腔崩解片剂。
与现有技术相比,本发明的有益效果是:
1)本发明所提供的含有枸橼酸西地那非和喷雾干燥乳糖的口腔崩解组合物用料安全,活性物质不易吸湿变质,该口崩片能在口腔唾液中迅速崩解而释放药物,适合患者在无水条件下以及吞咽困难的患者服用,具有质量稳定、易于服用、起效迅速、口感良好等优点。
2)本发明所涉及的口崩片制备简单、易于工业化生产。
附图说明
图1 为枸橼酸西地那非粒径分布图;
图2 为枸橼酸西地那非口崩片溶出曲线(0.01M盐酸介质);
图3 为枸橼酸西地那非口崩片0天样品溶出曲线对比图(0.01M盐酸介质);
图4 为枸橼酸西地那非口崩片加速6月样品溶出曲线对比图(0.01M盐酸介质);
图5 为枸橼酸西地那非口崩片含量检测HPLC图。
具体实施方式
现通过以下实施例来进一步描述本发明的制备过程和实施效果,但本发明的保护范围并不局限于以下实施例。
实验设备:
pH计(S210-K、梅特勒-托利多国际贸易(上海)有限公司)、激光粒度仪(马尔文3000、马尔文帕纳科)、高效液相色谱仪(岛津LC-20AT,UV检测器)。
检测方法:
参考马尔文3000干法测定及湿法测定SOP进行粒径测定;参照枸橼酸西地那非片国家药品标准中的含量测定方法和有关物质测定方法进行测定。
实施例1
1、处方
2、制备方法
将枸橼酸西地那非粉碎至粒度(D90)小于15 μm,与处方量的喷雾干燥乳糖混合均匀,再加入微晶纤维素、交联羧甲基纤维素钠、甜菊素、薄荷香精以及胶态二氧化硅混合均匀,最后加入处方量的硬脂酸镁,混合均匀后压片即得。
实施例2
1、处方
2、制备方法
将枸橼酸西地那非粉碎至粒度(D90)小于15μm,与处方量的喷雾干燥乳糖混合均匀,再加入交联羧甲基纤维素钠、甜菊素、薄荷香精以及胶态二氧化硅混合均匀,最后加入处方量的硬脂酸镁,混合均匀后压片即得。
实施例3
1、处方
2、制备方法
将枸橼酸西地那非粉碎至粒度(D90)小于15μm,与处方量的喷雾干燥乳糖混合均匀,再加入微晶纤维素、交联聚维酮、甜菊素、薄荷香精以及滑石粉混合均匀,最后加入处方量的硬脂酸镁,混合均匀后压片即得。
实施例4
1、处方
2、制备方法
将枸橼酸西地那非粉碎至粒度(D90)小于15μm,与处方量的喷雾干燥乳糖混合均匀,再加入三氯蔗糖、交联聚维酮、甜菊素、薄荷香精以及滑石粉混合均匀,最后加入处方量的硬脂酸镁,混合均匀后压片即得。
对比例1(处方工艺参照CN201510134423.7)
1、处方
2、制备方法
(1)将处方量的枸橼酸西地那非加入纯水中,搅拌使溶解,然后加入甲基纤维素,搅拌溶解,干燥除去水分,得到混合粉末,过60目筛;
(2)处方量称取过60目筛的乳糖、微晶纤维素与交联聚维酮,混合均匀;
(3)将步骤(1)与步骤(2)粉末混合均匀,加入处方量硬脂酸镁,混合均匀,压片而成。
对比例2(处方工艺参照CN200810166942.1)
1、处方
2、制备方法
按处方取枸橼酸西地那非和稀释剂、崩解剂、混合均匀得混合物;取聚维酮K30,溶于乙醇溶液中,制成含有2%聚维酮K30乙醇溶液;在步骤1的混合物中加入2%浓度的聚维酮K30的乙醇溶液,过20目筛制成颗粒,40-60℃干燥后,16目筛整粒;在整粒后加入润滑剂、矫味剂,压片,即得。
实施例5:枸橼酸西地那非口腔崩解片质量检测
1、含量检查。用十八烷基硅烷键合硅胶为填充剂;0.05mol/L磷酸三乙胺(取三乙胺7ml,用水稀释至1000ml,用磷酸调节pH值至3.0)-甲醇-乙腈(58:25:17)为流动相;检测波长为290nm。取枸橼酸西地那非对照品约70mg,置250mg量瓶中,加甲酸-过氧化氢(1:2)混合溶液1ml,加流动相溶解并稀释至刻度,取20μl注入液相色谱仪,西地那非与降解产物峰的分离度应大于2.5,理论塔板数按西地那非峰计算应不低于3000。测定法:取本品1片,置250ml量瓶中,加乙腈-水(9:1)5ml,振摇使溶解,以每分钟6000转离心10分钟,取上清液适量,用流动相稀释制成每1ml中约含西地那非20μg的溶液,作为供试品溶液,精密量取记录色谱图;另取枸橼酸西地那非对照品,精密称定,加流动相溶解并稀释制成每1ml约含西地那非20μg的溶液,同法测定。按外标法以峰面积分别计算每片的含量,求出平均标示量,即得。
2、有关物质检查。取本品5片,研细,置250ml量瓶中,加入乙腈-水(9:1)25ml,振摇并超声5分钟使溶解,用流动相稀释至刻度,超声5分钟,磁力搅拌30分钟,以每分钟6000转离心10分钟,取上清液适量,用流动相吸湿成每1ml约含西地那非0.5mg的溶液,作为供试品溶液。精密量取供试品溶液适量,用流动相稀释制成每1ml约含西地那非2.5μg的溶液作为对照溶液。照含量测定项下的色谱条件,取对照溶液20μl,注入液相色谱仪,调节检测灵敏度,使主成分的峰高约为满量程的10%。再精密量取供试品溶液和对照溶液各20μl,注入液相色谱仪,记录色谱图至主成分峰保留时间的二倍。供试品色谱图中如有杂质峰,大于对照品主峰面积0.2倍的杂质峰不得多于1个,且峰面积不得大于对照品主峰面积的0.6倍(0.3%),各杂质峰面积的和不得大于对照溶液的主峰面积(0.5%)。
3、崩解时限检查。仪器装置:主要结构为一能升降的支架与下端镶有筛网的不锈钢管。升降的支架上下移动距离为10mm±lmm,往返频率为每分钟30次。 崩解篮 不锈钢管,管长30mm,内径13.0mm,不锈钢筛网(镶在不锈钢管底部)筛孔内径710μm。检查法:将不锈钢管固定于支架上,浸入1000ml杯中,杯内盛有温度为37℃±1℃的水约900ml,调节水位高度使不锈钢管最低位时筛网在水面下15mm±1mm。启动仪器。取本品1片,置上述不锈钢管中进行检查,应在60秒钟内全部崩解并通过筛网,如有少量轻质上漂或黏附于不锈钢管内壁或筛网,但无硬心者,可作符合规定论。重复测定6片,均应符合规定。如有1片不符合规定,应另取6片复试,均应符合规定。
3 .溶出度测定。取本品,照溶出度与释放度测定法(中国药典2020年版四部通则0931,第二法),以0.01M盐酸溶液900ml为溶出液,转速为每分钟100转,依法操作。经15分钟时,取溶液滤过,取续滤液5ml,用0.01M的盐酸溶液稀释至20ml作为供试品溶液。另取枸橼酸西地那非对照品适量,精密称定,用0.01M盐酸溶解并稀释成每1ml约含西地那非22μg的溶液,作为对照品溶液。取上述两种溶液,照紫外-可见分光光度法(中国药典2020年版四部通则0401,在290nm处分别测定吸收度,计算出每片的溶出量。限度为标示量的80%,应符合规定。
表1 稳定性试验结果
从表1的实验结果可知,本发明实施例1-4制备的枸橼酸西地那非片经加速试验后仍具有优良的崩解性能,释放迅速且完全,稳定性良好;而对比例经加速实验后崩解明显减慢,含量明显降低,溶出度明显不合格,稳定性较差。
Claims (9)
1.一种枸橼酸西地那非口腔崩解组合物,其特征在于,所述的枸橼酸西地那非口腔崩解组合物含有枸橼酸西地那非-喷雾干燥乳糖混粉及其他药学上可接受的辅料。
2.根据权利要求1所述的枸橼酸西地那非口腔崩解组合物,其特征在于,所述的枸橼酸西地那非口腔崩解组合物中枸橼酸西地那非具有这样的粒径分布:对应于90%所述分布的颗粒直径(D90)为 15μm 或更小。
3.根据权利要求1或2所述的枸橼酸西地那非口腔崩解组合物,其特征在于,所述的枸橼酸西地那非口腔崩解组合物中枸橼酸西地那非-喷雾干燥乳糖混粉中枸橼酸西地那非与喷雾干燥乳糖比例为1:(3-5)。
4.根据权利要求1所述的枸橼酸西地那非口腔崩解组合物,其特征在于,所述的枸橼酸西地那非口腔崩解组合物中其他药学上可接受的辅料包含崩解剂、填充剂、矫味剂和润滑剂。
5.根据权利要求4所述的枸橼酸西地那非口腔崩解组合物,其特征在于,所述的填充剂选自甘露醇、三氯蔗糖、微晶纤维素中的一种或几种。
6.根据权利要求4所述的枸橼酸西地那非口腔崩解组合物,其特征在于,所述的崩解剂选自交联羧甲基纤维素钠、交联聚维酮、交联羧甲基纤维素钙、羧甲基淀粉钠中的一种或几种。
7.根据权利要求4所述的枸橼酸西地那非口腔崩解组合物,其特征在于,所述的矫味剂选自为甜菊素、薄荷香精、糖精钠中的一种或几种。
8.根据权利要求4所述的枸橼酸西地那非口腔崩解组合物,其特征在于,所述的润滑剂选自硬脂酸镁、胶态二氧化硅和滑石粉中的一种或几种。
9.根据权利要求1所述的枸橼酸西地那非口腔崩解组合物,其特征在于,制备该枸橼酸西地拉非口腔崩解组合物包括以下步骤:
(a)将枸橼酸西地那非粉碎至粒度(D90)为 15μm 或更小;
(b)将已处理的枸橼酸西地那非、喷雾干燥乳糖加入三维混合机中,使其充分混合;
(c)在所得枸橼酸西地那非-喷雾干燥乳糖混粉中加入其他辅料混合均匀,得到中间体颗粒,压片即得枸橼酸西地那非口腔崩解片剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110525787.3A CN115337276B (zh) | 2021-05-14 | 2021-05-14 | 一种枸橼酸西地那非口腔崩解片剂的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110525787.3A CN115337276B (zh) | 2021-05-14 | 2021-05-14 | 一种枸橼酸西地那非口腔崩解片剂的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115337276A true CN115337276A (zh) | 2022-11-15 |
CN115337276B CN115337276B (zh) | 2024-02-09 |
Family
ID=83947360
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110525787.3A Active CN115337276B (zh) | 2021-05-14 | 2021-05-14 | 一种枸橼酸西地那非口腔崩解片剂的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115337276B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4916163A (en) * | 1985-06-04 | 1990-04-10 | The Upjohn Company | Spray-dried lactose formulation of micronized glyburide |
CN101485636A (zh) * | 2008-01-14 | 2009-07-22 | 齐鲁制药有限公司 | 利培酮口腔崩解片及其制备方法 |
TW201427721A (zh) * | 2012-12-14 | 2014-07-16 | Hanmi Pharm Ind Co Ltd | 包含磷酸二酯酶-5抑制劑的咀嚼錠 |
US20150216798A1 (en) * | 2012-08-17 | 2015-08-06 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Novel orally administered pharmaceutical formulations |
CN109939237A (zh) * | 2017-12-21 | 2019-06-28 | 万全万特制药(厦门)有限公司 | 含有孟鲁司特钠口崩片的制备方法 |
-
2021
- 2021-05-14 CN CN202110525787.3A patent/CN115337276B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4916163A (en) * | 1985-06-04 | 1990-04-10 | The Upjohn Company | Spray-dried lactose formulation of micronized glyburide |
CN101485636A (zh) * | 2008-01-14 | 2009-07-22 | 齐鲁制药有限公司 | 利培酮口腔崩解片及其制备方法 |
US20150216798A1 (en) * | 2012-08-17 | 2015-08-06 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Novel orally administered pharmaceutical formulations |
TW201427721A (zh) * | 2012-12-14 | 2014-07-16 | Hanmi Pharm Ind Co Ltd | 包含磷酸二酯酶-5抑制劑的咀嚼錠 |
CN109939237A (zh) * | 2017-12-21 | 2019-06-28 | 万全万特制药(厦门)有限公司 | 含有孟鲁司特钠口崩片的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN115337276B (zh) | 2024-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100738861B1 (ko) | 베타-카르볼린 약학 조성물 | |
RU2685724C2 (ru) | Композиции апиксабана | |
JP4456788B2 (ja) | β−カルボリン製剤 | |
RU2446800C2 (ru) | Препаративные формы с контролируемым высвобождением | |
US9707178B2 (en) | Pharmaceutical composition | |
JP2003503380A (ja) | 無定形硝酸エステルおよびその製剤組成物 | |
EA029586B1 (ru) | Фармацевтическая композиция для лечения вич-инфекций | |
EA035390B1 (ru) | Совместный осадок тадалафила с фармацевтически приемлемыми эксципиентами, содержащая его фармацевтическая композиция и способ их получения | |
WO2005115346A9 (en) | Pharmaceutical composition containing risperidone | |
CN109908104B (zh) | 一种阿莫西林胶囊及其制备方法 | |
CN114652692B (zh) | 一种治疗肝病的药物缓释片及其制备方法和用途 | |
CN115337276B (zh) | 一种枸橼酸西地那非口腔崩解片剂的制备方法 | |
CN105001223B (zh) | 一种恩替卡韦晶体化合物及其胶囊制剂 | |
CN106913528A (zh) | 阿哌沙班微丸及其制备方法 | |
KR0172134B1 (ko) | 고형 제제 | |
CN109846843B (zh) | 地氯雷他定口腔崩解片 | |
US10085991B2 (en) | Formulation inhibiting effects of low acid environment | |
CN114028348B (zh) | 一种枸橼酸西地那非口腔崩解片及其制备方法 | |
CN117338733B (zh) | 一种富马酸替诺福韦二吡呋酯片及其制备工艺 | |
CN103845292A (zh) | 泊沙康唑微丸及其制备方法 | |
CN108619106B (zh) | 缓慢释放的他克莫司药物组合物 | |
CN107961221B (zh) | 一种含有盐酸普拉格雷的药物组合物及其制备方法 | |
AU2019245827B2 (en) | Pharmaceutical composition comprising brexpiprazole | |
Ogwal et al. | Biovailability and stability of erythromycin delayed release tablets | |
CN104435119A (zh) | 五味子总木脂素有效部位固体分散体及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |